IRIS
FERRERI, ANDRES JOSE MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.618
EU - Europa 6.449
NA - Nord America 4.454
SA - Sud America 2.019
AF - Africa 156
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 2
Totale 20.718
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.197
RU - Federazione Russa 3.935
SG - Singapore 2.759
CN - Cina 2.181
BR - Brasile 1.626
HK - Hong Kong 1.059
VN - Vietnam 737
SE - Svezia 631
IT - Italia 611
FR - Francia 367
BD - Bangladesh 272
DE - Germania 254
GB - Regno Unito 194
AR - Argentina 146
FI - Finlandia 126
IN - India 121
CA - Canada 113
MX - Messico 83
EC - Ecuador 81
ID - Indonesia 81
AT - Austria 71
JP - Giappone 60
IQ - Iraq 48
ZA - Sudafrica 48
NL - Olanda 46
CO - Colombia 41
TR - Turchia 40
PY - Paraguay 37
PL - Polonia 36
IE - Irlanda 35
SA - Arabia Saudita 31
ES - Italia 29
CL - Cile 28
EG - Egitto 27
UA - Ucraina 27
VE - Venezuela 27
PK - Pakistan 22
MA - Marocco 20
MY - Malesia 20
PE - Perù 19
UZ - Uzbekistan 19
NP - Nepal 18
KR - Corea 17
PT - Portogallo 17
AU - Australia 16
IR - Iran 16
KE - Kenya 16
AE - Emirati Arabi Uniti 14
LT - Lituania 14
TN - Tunisia 14
JM - Giamaica 13
JO - Giordania 12
PH - Filippine 12
TT - Trinidad e Tobago 8
UY - Uruguay 8
DZ - Algeria 7
KZ - Kazakistan 7
PS - Palestinian Territory 7
TH - Thailandia 7
TW - Taiwan 7
BO - Bolivia 6
HN - Honduras 6
AL - Albania 5
AZ - Azerbaigian 5
CH - Svizzera 5
CI - Costa d'Avorio 5
CR - Costa Rica 5
CZ - Repubblica Ceca 5
GG - Guernsey 5
GT - Guatemala 5
IL - Israele 5
LB - Libano 5
NO - Norvegia 5
OM - Oman 5
SY - Repubblica araba siriana 5
YE - Yemen 5
BB - Barbados 4
BY - Bielorussia 4
ET - Etiopia 4
HR - Croazia 4
KW - Kuwait 4
NG - Nigeria 4
NI - Nicaragua 4
PA - Panama 4
RS - Serbia 4
BG - Bulgaria 3
DO - Repubblica Dominicana 3
LV - Lettonia 3
MD - Moldavia 3
MM - Myanmar 3
NZ - Nuova Zelanda 3
RO - Romania 3
SV - El Salvador 3
AM - Armenia 2
AO - Angola 2
BE - Belgio 2
BH - Bahrain 2
BS - Bahamas 2
GA - Gabon 2
GE - Georgia 2
Totale 20.691
Salva come PNG Salva come JPEG
Città #
Singapore 1.263
Hong Kong 1.053
Dallas 866
Moscow 845
San Jose 573
Ashburn 532
Shanghai 382
Hefei 345
Lauterbourg 298
Ho Chi Minh City 284
Lawrence 270
Princeton 270
Beijing 210
New York 191
Milan 138
São Paulo 136
Hanoi 134
Los Angeles 120
Santa Clara 89
Helsinki 85
Nuremberg 84
Rome 59
Munich 52
Orem 50
Belo Horizonte 47
Guangzhou 45
Rio de Janeiro 45
Montreal 38
Tokyo 36
Chennai 35
Dublin 34
Haiphong 32
Boardman 31
Da Nang 30
London 30
Turku 30
Biên Hòa 29
Vienna 29
Brasília 27
Brooklyn 27
Johannesburg 27
Mexico City 27
Toronto 27
Warsaw 27
Houston 26
Poplar 26
Guayaquil 25
Porto Alegre 25
Council Bluffs 24
Naples 24
Quito 24
Buffalo 23
Chicago 23
Hangzhou 23
Asunción 22
Mumbai 22
Stockholm 22
Denver 21
Manchester 20
Jakarta 19
Campinas 18
Frankfurt am Main 18
Leicester 18
Sorocaba 18
Tashkent 18
The Dalles 18
Atlanta 17
Boston 17
Osasco 17
Phoenix 17
Thái Bình 17
Baghdad 16
Goiânia 16
Tianjin 16
Amsterdam 15
Curitiba 15
Nairobi 15
San Francisco 15
Hải Dương 14
Santiago 14
Shenzhen 14
Buenos Aires 13
Columbus 13
Florence 13
Guarulhos 13
Salvador 13
Seattle 13
Washington 13
Caxias do Sul 12
Dhaka 12
Kuala Lumpur 12
Paris 12
Riyadh 12
Santo André 12
Daejeon 11
Ninh Bình 11
Ankara 10
Aracaju 10
Bắc Giang 10
Foshan 10
Totale 9.919
Salva come PNG Salva come JPEG
Nome #
Definition, diagnosis, and management of intravascular large B-Cell lymphoma: Proposals and perspectives from an international consensus meeting 335
Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Combination 197
Radiomics-Based Machine Learning Model for Predicting Overall and Progression-Free Survival in Rare Cancer: A Case Study for Primary CNS Lymphoma Patients 164
A multicenter study of treatment of primary CNS lymphoma 159
ABS0671 IgG4-RELATED DISEASE IN OVERLAP WITH IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE: CLINICAL-PATHOLOGICAL CHARACTERISTICS AND THERAPEUTIC IMPLICATIONS OF AN ORPHAN DISEASE 151
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the “CARMEN” phase II trial 150
BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome 143
THREE-HOUR INFUSION OF METHOTREXATE AT 3 g/m2 SIGNIFICANTLY REDUCES CNS RELAPSES AND IMPROVES SURVIVAL IN PATIENTS WITH LARGE B-CELL LYMPHOMAS AND INCREASED CNS RISK 139
Chronic lymphocytic leukaemia 131
A MULTICENTER TRIAL ASSESSING FEASIBILITY AND EFFICACY OF A COMBINATION OF HIGH-DOSE METHOTREXATE, CYTARABINE AND THIOTEPA IN PATIENTS WITH PRIMARY CNS LYMPHOMA: IMPACT ON OUTCOME OF CYTARABINE DOSE 129
Diagnosis and Treatment Using Autologous Stem-Cell Transplantation in Primary Central Nervous System Lymphoma: A Systematic Review 127
Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy 127
A PHASE II STUDY TO INVESTIGATE THE PREVALENCE OF INFECTIOUS AGENTS IN OCULAR ADNEXAE MARGINAL ZONE LYMPHOMA (OAMZL) AND THE EFFICACY OF ANTIBIOTIC THERAPY (IELSG#27 TRIAL) 127
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL 125
Liquid biopsy of cerebrospinal fluid enabling the detection and therapeutic targeting of the BRAFV600E mutation in a patient with overlapping Erdheim-Chester/Rosai-Dorfman disease 123
Central nervous system marginal zone B-cell lymphoma associated with chlamydophila psittaci infection 119
A virtual tissue bank for primary central nervous system lymphomas in immunocompetent individuals 116
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study 112
Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: Final results of a phase 2 trial 111
SHORT-TERM DOSE-DENSE “CARMEN” THERAPY IS BETTER TOLERATED AND EVENLY EFFECTIVE THAN OTHER INTENSIFIED REGIMENS IN HIV- AND HIV+ PATIENTS WITH BURKITT LYMHOMA 110
Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi 110
A Six-Month Regimen of Oral Clarithromycin Is a Feasible and Active Therapy for Patients with Relapsed/Refractory Marginal Zone B-Cell Lymphoma of MALT-Type 110
Quantitative muscle mass biomarkers are independent prognosis factors in primary central nervous system lymphoma: The role of L3-skeletal muscle index and temporal muscle thickness 103
Anti-CD20 monoclonal antibody (Rituximab) in gastric extranodal marginal zone (MALT) non-Hodgkin's lymphoma (NHL) patients: Clinical and biological results (Phase II study). 102
A PHASE II TRIAL TO INVESTIGATE THE LINK WITH INFECTIOUS AGENTS IN OCULAR ADNEXAL MARGINAL ZONE LYMPHOMA, ESPECIALLY WITH CHLAMYDIA SPECIES, AND THE ANTINEOPLASTIC EFFECTS OF DOXYCYCLINE (IELSG#27) 101
ABVD CAN BE SAFELY ADMINISTERED REGARDLESS OF ABSOLUTE NEUTROPHIL COUNT AND WITHOUT G-CSF SUPPORT IN HODGKIN'S LYMPHOMA PATIENTS 101
Aggressive B-cell lymphoma with MYC/TP53 dual alterations displays distinct clinicopathobiological features and response to novel targeted agents 100
A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma 100
ORBIT IRRADIATION AS SALVAGE TREATMENT FOR PATIENTS WITH OCULAR ADNEXAL MALT LYMPHOMA (OAML) RELAPSED AFTER OR REFRACTORY TO CHLAMYDIA PSITTACI-ERADICATING ANTIBIOTIC THERAPY 98
Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells 97
Graft-versus-lymphoma effect inside the central nervous system in a patient with extranodal natural killer/T-cell lymphoma, nasal type 97
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: Results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial 96
A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: The TIER trial 96
Bone Marrow Histopathology in the Diagnostic Evaluation of Splenic Marginal-zone and Splenic Diffuse Red Pulp Small B-cell Lymphoma: A Reliable Substitute for Spleen Histopathology? 93
Activity of rituximab in extranodal marginal zone lymphomas (MALT-type). 93
The impact of histopathologic diagnosis on the proper management of testis neoplasms 92
A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphoma 92
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation 91
Primary central nervous system lymphoma 91
Clinical Experience in a Large Cohort of Patients with Vitreoretinal Lymphoma in a Single Center 89
MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study 89
Adjuvant chemotherapy in ductal adenocarcinoma of pancreas: a comparison among three regimens 89
Salvage Irradiation for Ocular Adnexal Mucosa Associated Lymphoid Tissue Lymphoma Refractory to Chlamydia psittaci Eradication 89
Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis 88
FEASIBILITY AND EFFICACY OF CHLAMYDIA PSITTACI ERADICATION WITH PROLONGED DOXYCYCLINE THERAPY IN LOCALIZED OCULAR ADNEXAE MARGINAL ZONE LYMPHOMA (OAMZL): 7-YEAR RESULTS OF THE IELSG39 MULTICENTER TRIAL 88
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma 88
Chronic lymphocytic leukemia 86
Chlamydia infection and lymphoma: Multiple detection methods highlight an association beyond lymphomas of the ocular adnexa 86
Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL 86
A retrospective analysis of postradiation chemotherapy in 133 patients with glioblastoma multiforme 86
Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy 85
High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial 85
A retrospective series of upfront therapy in primary brain lymphomas 85
Deep learning-based overall survival prediction model in patients with rare cancer: a case study for primary central nervous system lymphoma 84
Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas 84
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study 83
Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma 83
New hopes in relapsed refractory primary central nervous system lymphoma 82
Prevention and management of secondary central nervous system lymphoma 82
Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study) 82
Gamma-delta t-cell lymphomas 81
Targeting the Blood–Brain Tumor Barrier with Tumor Necrosis Factor-α 80
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas 80
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial 78
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial 77
Cyclin D3 immunoreactivity (IR) is an independent predictor of survival and drives the correct assessment of p27(KIP1) IR prognostic role in primary gastric lymphomas (PGL). 75
Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas 74
Cyclin D3 (CyD3) immunoreactivity (IR) is an independent predictor of survival and drives the correct assessment of p27 IR prognostic role in primary gastric lymphomas (PGL) 73
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy 71
Mantle cell lymphoma 71
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: A FIL study 70
Six-Month Doxycycline Is Safe and Effective As Upfront Monotherapy for Stage-I Malt Lymphoma of the Ocular Adnexae: Primary Endpoint Results of the IELSG39 Trial 69
Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta-analysis 69
Lymphoblastic lymphoma 69
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial 69
Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG) 69
Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma 68
Rituximab in patients with mucosal-associated lymphold tissue-type lymphoma of the ocular adnexa 68
Prevalence of Borrelia Burgdorferi Infection in a Series of 98 Primary Cutaneous Lymphomas 68
Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue 68
AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma 68
Chlamydia infection and lymphomas: association beyond ocular adnexal lymphomas highlighted by multiple detection methods 68
Le infezioni erpetiche nel paziente immunocompromesso 68
Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma project 67
Clinical features, management and prognosis of multifocal primary bone lymphoma: A retrospective study of the international extranodal lymphoma study group (the IELSG 14 study) 67
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial 67
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53 67
Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy 67
Primary central nervous system lymphomas: Salvage treatment after failure to high-dose methotrexate 67
Systemic vs. intrathecal central nervous system prophylaxis in primary adrenal/renal diffuse large b-cell LYMPHOMA: A multi-institution retrospective analysis and systematic review 67
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type 66
Cellular Senescence Markers p16(INK4a) and p21(CIP1/WAF) Are Predictors of Hodgkin Lymphoma Outcome 66
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms 65
ALK-negative anaplastic large cell lymphoma: Features and outcomes of 235 patients from the International T-Cell Project 65
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL) 65
Ocular Adnexal Lymphoma: Diffusion-weighted MR Imaging for Differential Diagnosis and Therapeutic Monitoring 65
Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions 65
First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: A phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia 65
Applying data warehousing to a phase III clinical trial from the Fondazione Italiana Linfomi ensures superior data quality and improved assessment of clinical outcomes 64
Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III-IV diffuse large B cell lymphomas 64
Totale 9.327
Salva come PNG Salva come JPEG
Categoria #
all - tutte 134.212
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 134.212
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022232 0 0 2 71 9 6 16 91 4 5 1 27
2022/20231.341 631 271 56 6 9 135 42 86 53 10 17 25
2023/2024899 39 36 42 58 238 123 57 67 36 52 47 104
2024/20254.272 560 63 44 124 134 340 451 307 859 776 275 339
2025/202614.283 912 1.187 1.279 2.134 1.027 318 1.239 939 3.655 717 378 498
Totale 21.083